BSG
GERM

Black Swift Group’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Black Swift Group’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,000
Closed -$143K – 133
2020
Q2 		$143K Buy
+5,000
New +$135K 0.1% 54

Other funds holding GERM

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return

Black Swift Group's GERM Position: Q3 2020 in Review

Black Swift Group sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2020, closing a stake of 5,000 shares — an estimated $143K sold.

Black Swift Group first reported a position in GERM in Q2 2020 and held it in 1 quarter. The position peaked at $143K in Q2 2020. 20 funds tracked by Wall St. Rank hold GERM as of Q3 2020.

  • Black Swift Group reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2020 after selling out during the quarter.
  • Black Swift Group sold 5,000 Amplify Treatments, Testing and Advancements ETF shares in Q3 2020, an estimated $143K.
  • Black Swift Group first reported a position in Amplify Treatments, Testing and Advancements ETF in Q2 2020 and held it in 1 quarter.
  • Black Swift Group's Amplify Treatments, Testing and Advancements ETF position peaked at $143K in Q2 2020.
  • 20 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2020.

Based on Black Swift Group's 13F filing for Q3 2020, filed 5 Feb 2021.